2-(6-ethyl-1-benzofuran-3-yl)-N-(4-pyridin-2-yl-1,3-thiazol-2-yl)acetamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: 2-(6-ethyl-1-benzofuran-3-yl)-N-(4-pyridin-2-yl-1,3-thiazol-2-yl)acetamide
• 化学式: C₂₀H₁₇N₃O₂S
• 分子量: 363.4
• InChiKey: DJNWLFPFLKXYDT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  96.3
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• BENZOFURAN AMIDES AND HETEROAROMATIC ANALOGUES THEREOF FOR USE IN THERAPY
  申请人：European Molecular Biology Laboratory

  公开号：US20200223837A1

  公开（公告）日：2020-07-16

  The present invention relates to a pharmaceutical composition comprising a compound of the formula I as described below or a tautomer or a pharmaceutically acceptable salt thereof; to the compound of the formula I as described below or a tautomer or a pharmaceutically acceptable salt thereof for use as a medicament, especially for use in the treatment or prevention of a disease or disorder selected from the group consisting of an inflammatory disease, a hyperproliferative disease or disorder, a hypoxia-related pathology and a disease characterized by excessive vascularization, and to certain novel compounds of the formula I as described below or a tautomer or a pharmaceutically acceptable salt thereof. Formula (I) wherein X 1 is CR 1 or N; X 2 is CR 2 or N; X 3 is CR 3 or N; X 4 is CR 4 or N; with the proviso that at most two of X 1 , X 2 , X 3 and X 4 are N; L 1 , L 2 are a bond or a bivalent radical such as C 1 -C 6 -alkylene or C 3 -C 8 -cycloalkylene; A is 3-, 4-, 5-, 6-, 7- or 8-membered saturated, partially unsaturated or maximally unsaturated carbocyclic ring which may carry one or more substituents R 9 ; or L 2 -A forms a group C 1 -C 6 -alkylene-OR 13 , C 1 -C 6 -alkylene-SR 14 or C 1 -C 6 -alkylene-NR 15 R 16 ; and R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 9 , R 13 , R 14 , R 15 and R 16 are as defined in the claims and the description.